New Delhi: Alembic Pharmaceuticals today said it along with Breckenridge Pharmaceutical Inc, USA has settled patent case with Novartis for Rivastigmine Tartrate capsules used for treating dementia. The companies have settled their Paragraph IV patent litigation with Novartis for Rivastigmine Tartrate capsules which are a generic version of Exelon capsules of Novartis, Alembic Pharmaceuticals said in a filing to BSE. Under the terms of the settlement agreement, Novartis has granted the two companies a licence to market their generic capsules before the date of the patent expiry, it added. The companies will launch the product immediately in the American market, Alembic Pharmaceuticals said.
BCCI to restrict WAGs during foreign tours?
Govt bans film on Indira`s assassination
Power my govt`s first priority: PM Modi
Maharashtra CM Prithviraj Chavan not to share dais with Narendra Modi